RSV and rhinovirus increase pneumococcal carriage acquisition and density, whereas nasal inflammation is associated with bacterial shedding.

RSV Rhinovirus S.pneumoniae bacterial shedding co-infection nasal inflammation pneumococcal carriage transmission

Journal

Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316

Informations de publication

Date de publication:
17 Aug 2024
Historique:
received: 15 02 2024
revised: 14 06 2024
accepted: 29 07 2024
medline: 26 8 2024
pubmed: 26 8 2024
entrez: 24 8 2024
Statut: aheadofprint

Résumé

Epidemiological studies report the impact of co-infection with pneumococcus and respiratory viruses upon disease rates and outcomes, but their effect on pneumococcal carriage acquisition and bacterial load is scarcely described. Here, we assess this by combining natural viral infection with controlled human pneumococcal infection in 581 healthy adults screened for upper respiratory tract viral infection before intranasal pneumococcal challenge. Across all adults, respiratory syncytial virus (RSV) and rhinovirus asymptomatic infection confer a substantial increase in secondary infection with pneumococcus. RSV also has a major impact on pneumococcal density up to 9 days post challenge. We also study rates and kinetics of bacterial shedding through the nose and oral route in a subset. High levels of pneumococcal colonization density and nasal inflammation are strongly correlated with increased odds of nasal shedding as opposed to cough shedding. Protection against respiratory viral infections and control of pneumococcal density may contribute to preventing pneumococcal disease and reducing bacterial spread.

Identifiants

pubmed: 39181126
pii: S1931-3128(24)00283-X
doi: 10.1016/j.chom.2024.07.024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Elena Mitsi (E)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, UK; Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK. Electronic address: elena.mitsi@paediatrics.ox.ac.uk.

Elissavet Nikolaou (E)

Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC 3052, Australia.

Andre Goncalves (A)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, UK; Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.

Annie Blizard (A)

Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.

Helen Hill (H)

Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.

Madlen Farrar (M)

Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.

Angela Hyder-Wright (A)

Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.

Oluwasefunmi Akeju (O)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, UK.

Josh Hamilton (J)

Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.

Ashleigh Howard (A)

Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.

Filora Elterish (F)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, UK.

Carla Solorzano (C)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, UK; Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.

Ryan Robinson (R)

Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.

Jesus Reiné (J)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, UK; Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.

Andrea M Collins (AM)

Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.

Stephen B Gordon (SB)

Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK; Malawi Liverpool Wellcome-Trust Programme, Queen Elizabeth Central Hospital Campus, P.O. Box 30096, Blantyre, Malawi.

Richard E Moxon (RE)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, UK.

Jeffrey N Weiser (JN)

Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA.

Debby Bogaert (D)

Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK; Department of Paediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Centre Utrecht, 3584 EA Utrecht, the Netherlands.

Daniela M Ferreira (DM)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford OX3 7LE, UK; Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK. Electronic address: daniela.ferreira@paediatrics.ox.ac.uk.

Classifications MeSH